Table 2 Number of patients’ samples for gene expression profiling
From: An expression signature at diagnosis to estimate prostate cancer patients’ overall survival
Na | ||||
|---|---|---|---|---|
Feature | Subset 1 | Subset 2 | Subset 3 | Complete set |
Total | 36 | 65 | 88 | 189 |
CTGF | 36 | — | 67 | 103 |
FBP1 | 36 | — | 46 | 82 |
EGR1 | 26 | 65 | 88 | 179 |
CYR61 | 36 | — | 46 | 82 |
WNT5B | 36 | — | 56 | 92 |
LRP4 | 28 | — | — | 28 |
CDH1 | 36 | — | — | 36 |
BASP1 | 28 | 65 | 88 | 181 |
PTN | 28 | — | — | 28 |
COL12A1 | 28 | 64 | 88 | 180 |
VGLL3 | 28 | 40 | 88 | 156 |
METTL7A | 36 | — | — | 36 |
F3 | 28 | — | 67 | 95 |
GREM1 | 36 | — | — | 36 |
ERBB3 | 36 | — | 56 | 92 |
LRNN1 | 36 | 62 | 88 | 186 |
THBS1 | 28 | — | — | 28 |
IGFBP3 | 26 | 59 | 88 | 173 |
WNT11 | 28 | 65 | 88 | 181 |
c-MAF-a | 26 | 64 | 88 | 178 |
c-MAF-b | 26 | — | 46 | 72 |
AZGP1 | — | 63 | 88 | 151 |
AMACR | — | 63 | 88 | 151 |
MUC1 | — | 58 | 88 | 146 |
EZH2 | — | 59 | 88 | 147 |
The ESCGP signatureb | 28 | — | 67 | 95 |
